Lupin gets approval from FDA for generic drug for dementia
Advertisement
USFDA has recently given its approval to the pharma major Lupin to market generic Aricept tablets used for treatment of dementia.
The company's US subsidiary, Lupin Pharmaceuticals, would commence promoting the product shortly in the US, to grab a share of the lucrative Aricept US sales of $52.3 million (IMS MAT June 2015).
"...it has received final approval for its Donepezil Hydrochloride Tablets, 23 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eisai Inc's Aricept tablets," it added.
The company's US subsidiary, Lupin Pharmaceuticals, would commence promoting the product shortly in the US, to grab a share of the lucrative Aricept US sales of $52.3 million (IMS MAT June 2015).
"...it has received final approval for its Donepezil Hydrochloride Tablets, 23 mg from the United States Food and Drug Administration (FDA) to market a generic version of Eisai Inc's Aricept tablets," it added.
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.